Test Price
2,800 AED✅ Home Collection Available
ZDHHC15 Gene X‑Linked Intellectual Disability Type 91 Genetic Test in UAE | 2,800 AED | DHA‑Licensed NGS Diagnostics
Executive Summary & Core Metrics
🔬 Accuracy Guarantee
99.9% Diagnostic Sensitivity via ISO 9001:2015‑Certified Next‑Generation Sequencing (NGS) processing with Sanger confirmation.
🚚 Premium Logistics
VIP Mobile Phlebotomy & Temperature‑Controlled Cold‑Chain Home Collection (daily 8 AM – 11 PM).
🧬 Clinical Guidance
Telephonic Post‑Test Genetic Counselling by a DHA‑licensed Consultant Medical Genetics professional.
💳 Insurance & Billing
Direct Billing Verification via WhatsApp +971 54 548 8731.
Test Overview & Methodology
The ZDHHC15 gene NGS test detects pathogenic variants causing X‑linked intellectual disability type 91 (MRX91) by sequencing all coding exons and flanking splice junctions. This targeted molecular diagnosis enables precise clinical management, genetic counselling, and informed family planning for affected individuals and their relatives.
Analysis is performed on peripheral whole blood using a custom hybrid‑capture NGS panel validated for >99.9% sensitivity and specificity across the ZDHHC15 coding region. All clinically significant findings are confirmed through Sanger sequencing prior to report release.
| Feature | Our NGS Test | Closest Alternative (Whole‑Exome Sequencing) |
|---|---|---|
| Diagnostic Precision | 99.9% sensitivity & specificity for ZDHHC15 | ~95% depending on coverage; may miss deep intronic variants |
| Methodology | Custom NGS panel with Sanger validation | Broad exome capture; secondary findings possible |
| Turnaround Time | 3–4 weeks | 6–10 weeks (often longer) |
Physician Insight & Safety Protocols
“Families seeking answers for unexplained developmental delays face a complex emotional and medical journey. This targeted ZDHHC15 NGS test delivers a definitive molecular diagnosis when clinical suspicion points to X‑linked inheritance. A pathogenic finding enables tailored early intervention, accurate recurrence risk counselling, and informed family planning decisions. Every result must be interpreted within the full clinical context, and our genetics team provides continuous support from pre‑test counselling through post‑report discussion.”
— Lina Osama Zaki Quteineh, Consultant Medical Genetics, DHA Registration ID: 9294403
Medication Advisory
Do not discontinue, adjust, or alter any prescribed medication without consulting your treating physician. This genetic test is a diagnostic aid and does not replace ongoing clinical management or therapeutic oversight.
Safety Exclusion Criteria & Emergency Red Flags
- Exclusion: Inability to provide informed consent (guardian consent mandatory per UAE Federal Decree‑Law No. 4 of 2016 on Medical Liability for minors); active bleeding disorder contraindicating venipuncture; severe anaemia or compromised peripheral vein access.
- Emergency Red Flags: Acute psychiatric distress, severe anxiety, new‑onset seizures, loss of consciousness, or any acute medical deterioration during the pre‑test visit – suspend the procedure and transfer to emergency care immediately.
Patient FAQ & Clinical Guidance
1. Who should consider the ZDHHC15 Genetic Test?
Males with unexplained intellectual disability, developmental delay, or autistic features and a family history suggestive of X‑linked inheritance are the primary candidates. Females with affected male relatives may also undergo testing to determine carrier status and assess reproductive risk.
2. What does a positive result mean for family planning?
Detection of a pathogenic ZDHHC15 variant confirms X‑linked intellectual disability type 91 and enables precise recurrence risk calculation: a carrier mother has a 50% chance of transmitting the variant to each son (who would be affected) and a 50% chance to each daughter (who would be a carrier). Genetic counselling provides detailed discussion of prenatal and preimplantation testing options.
3. How is my genetic data protected under UAE law?
All genetic information is handled in full compliance with Federal Decree‑Law No. 45 of 2021 on Personal Data Protection (PDPL) and Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields. Data is encrypted during transmission and storage, access is restricted to authorised clinical personnel only, and results are never shared without explicit written consent. The laboratory operates under an ISO 9001:2015‑certified quality management system.
UAE Regulatory & Data Privacy Adherence
Your privacy and safety are protected by UAE federal law.
- Data Protection: All personal and genetic data processed under Federal Decree‑Law No. 45 of 2021 (PDPL).
- Health Information Governance: Full compliance with Federal Law No. 2 of 2019 governing health ICT use.
- Clinical Safety & Consent: Procedures and patient consent adhere to Federal Decree‑Law No. 4 of 2016 on Medical Liability.
- Quality Certification: DNA Labs UAE operates under an ISO 9001:2015‑certified management system with regular external audits.
Clinical & Logistical Metadata
| Test Name | ZDHHC15 Gene X‑Linked Intellectual Disability Type 91 Genetic Test |
| Price (AED) | 2,800 AED |
| Turnaround Time | 3–4 weeks |
| Sample Type / Matrix | Whole blood (peripheral venipuncture) |
| Methodology Used | Custom NGS Panel with Sanger confirmation |
| ICD-10-CM Code | F78.9 |
| LOINC Code | 94847-3 |
| DHA Facility License & Laboratory Address | DHA Facility License Number: 1143 – DNA Labs UAE, Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE |
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians